Academic Career and Research Areas
Professor Bassermann conducts research into the molecular pathophysiology of malignant diseases. His work is focused in particular on aberrant mechanisms in ubiquitin-dependent signalling pathways. These pathways play a key role in the regulation of cellular processes which are relevant for tumors, including immune and cell cycle regulation, the cellular response to DNA damage, cell metabolism and programmed cell death. These findings are then applied in translational studies, where they are investigated for their significance for pathogenesis and also for the therapeutical treatment of hematological and solid tumors.
Professor Bassermann studied medicine in Ulm, Munich and New York, and obtained his doctorate from TUM in 2002. He began his work as a physician and researcher at TUM before going to New York University, where he worked as a post-doctoral researcher from 2006 to 2009. After returning to TUM, he took on the leadership of an Emmy Noether Junior Research Group funded by the German Research Foundation (DFG), qualified as a specialist in internal medicine and hematology/oncology, and completed his post-doctoral teaching qualification. In 2011 he was appointed as senior physician and in 2015 he was offered a Tenure Track Professorship at TUM. Since 2017, Professor Bassermann has been director of the Clinic and Polyclinic for Internal Medicine III (Hematology / Oncology) at the TUM Rechts der Isar Hospital.
- ERC Consolidator Grant (2015)
- Langener Science Award (2015)
- Theodor Frerichs Prize awarded by the German Society of Internal Medicine - DGIM (2015)
- Walther Flemming Medal awarded by the German Society of Cellular Biology (DGZ) (2010)
- Member of the Emmy Noether Program of the German Research Foundation - DFG (2009)
Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F: "Immunomodulatory drugs disrupt the CRBN-CD147/MCT1 axis to exert anti-tumor activity and teratogenicity". Nature Medicine. 2016; 22(7): 735-743.Abstract
Baumann U., Fernandez-Saiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F: „Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis“. Nature Medicine. 2014; 20(12): 1401-1409.Abstract
Fernández-Sáiz V, Targosz BS, Lemeer S, Eichner R, Langer C, Bullinger L, Reiter C, SlottaHuspenina J, Schroeder S, Knorn, AM, Kurutz J, Peschel C, Pagano M, Kuster B, Bassermann F: “SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma”. Nature Cell. Biol. 2013; 15(1): 72-81.Abstract
Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M: “The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA damage response checkpoint”. Cell. 2008; 134(2): 256-267.Abstract
Bassermann F, von Klitzing C, Muench S, Bai RY, Kawaguchi H, Morris SW, Peschel C, Duyster J: “NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry”. Cell. 2005; 122(1): 45-57.Abstract